- Home
- BIIB vs PPL Comparison
BIIB vs PPL Comparison
Compare BIIB & PPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- PPL
- Stock Information
- Founded
- BIIB 1978
- PPL 1920
- Country
- BIIB United States
- PPL United States
- Employees
- BIIB N/A
- PPL N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- PPL Electric Utilities: Central
- Sector
- BIIB Health Care
- PPL Utilities
- Exchange
- BIIB Nasdaq
- PPL Nasdaq
- Market Cap
- BIIB 25.1B
- PPL 23.8B
- IPO Year
- BIIB 1991
- PPL N/A
- Fundamental
- Price
- BIIB $150.21
- PPL $32.64
- Analyst Decision
- BIIB Buy
- PPL Buy
- Analyst Count
- BIIB 26
- PPL 12
- Target Price
- BIIB $248.00
- PPL $35.58
- AVG Volume (30 Days)
- BIIB 1.6M
- PPL 4.0M
- Earning Date
- BIIB 02-11-2025
- PPL 02-14-2025
- Dividend Yield
- BIIB N/A
- PPL 3.17%
- EPS Growth
- BIIB 10.05
- PPL 1.20
- EPS
- BIIB 11.06
- PPL 1.11
- Revenue
- BIIB $9,607,500,000.00
- PPL $8,282,000,000.00
- Revenue This Year
- BIIB N/A
- PPL $0.66
- Revenue Next Year
- BIIB N/A
- PPL $0.80
- P/E Ratio
- BIIB $13.47
- PPL $29.36
- Revenue Growth
- BIIB N/A
- PPL N/A
- 52 Week Low
- BIIB $145.07
- PPL $25.35
- 52 Week High
- BIIB $268.30
- PPL $35.15
- Technical
- Relative Strength Index (RSI)
- BIIB 31.81
- PPL 44.93
- Support Level
- BIIB $145.07
- PPL $31.52
- Resistance Level
- BIIB $149.92
- PPL $32.78
- Average True Range (ATR)
- BIIB 3.57
- PPL 0.50
- MACD
- BIIB 0.18
- PPL -0.06
- Stochastic Oscillator
- BIIB 22.27
- PPL 40.65
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About PPL PPL Corporation
PPL is a holding company of regulated utilities in Pennsylvania, Kentucky, and Rhode Island. The Pennsylvania regulated delivery and transmission segment distributes electricity to customers in central and eastern Pennsylvania. LG&E and KU are involved in regulated electricity generation, transmission, and distribution in Kentucky. The Kentucky utilities also serve gas customers. Rhode Island Energy operates electric and gas utilities in Rhode Island.